Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine — Competitive Intelligence Brief

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine (Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy regimen Oncology Small molecule

Target snapshot

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine (Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine) — National Cancer Center, Korea. This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine TARGET	Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine	National Cancer Center, Korea	phase 3	Combination chemotherapy regimen
Carboplatin, Etoposide, Ifosfamide	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

1. Sun Yat-sen University · 5 drugs in this class
2. Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
3. Hoffmann-La Roche · 2 drugs in this class
4. University Hospital, Bordeaux · 2 drugs in this class
5. Beijing Friendship Hospital · 1 drug in this class
6. Centre Hospitalier Universitaire Dijon · 1 drug in this class
7. Amgen · 1 drug in this class
8. Chungnam National University Hospital · 1 drug in this class
9. AstraZeneca · 1 drug in this class
10. Children's Cancer Group, China · 1 drug in this class